Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02409121 · ClinicalTrials.gov registry record · NA

A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers

A NA study of Lymphoma and Leukemia, sponsored by University of Michigan Rogel Cancer Center.

Completed
Registry status
NA
Development phase
59
Enrollment target
1
Study location

NCT02409121 is a NA study of Lymphoma and Leukemia that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 59 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02409121, a NA study of Lymphoma and Leukemia, has completed, sponsored by University of Michigan Rogel Cancer Center.

COMPLETED
Registry status
NA
Development phase
59 participants
Enrollment target
1
Study location

Study Summary

Hematopoietic cell transplantation (BMT), or commonly referred to as blood and marrow transplantation (BMT), is a potentially life-saving therapy for many malignant and non-malignant conditions. Despite advances over the past decade, which have led to improved outcomes, BMT remains an intense treatment modality often requiring prolonged inpatient-based care. While many patients endure the acute complications of the procedure, it is common for BMT patients and their caregivers to experience increased risk of financial and emotional burden, hospital readmission, and health service utilization. This highlights the importance of active involvement of BMT patients in their own health care (self-efficacy). For pediatric BMT patients, parents are the primary caregivers. As such, parental activation on behalf of the child (patient) plays a critical role in effective patient-parent-provider partnerships, which is increasingly recognized as the optimal model for health care delivery, particularly for those facing life-altering medical treatments. It is essential to develop effective strategies to enhance this partnership. Health information technology (IT)-mediated tools offer the potential to overcome constraints in health care delivery limited by provider time, complicated health information, and financial pressures. Significant gaps in knowledge exist on the use of health IT tools using low-cost and well-accepted delivery platforms in routine inpatient care, especially for high-risk or critically ill populations. The investigators hypothesize that a tablet-based tool displaying personal health information could provide a platform to promote caregiver (parent) activation and enhance health communication. In this clinical research study, the investigators will conduct a pilot study of an educational health IT system developed on a tablet (Apple iPad®) that the investigators refer to as a Personalized Engagement Tool (PET) or the "BMT Roadmap." The Apple iPad® was selected as

Interventions

  • BEHAVIORAL Education information system

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2015-09
Est. Completion 2018-12-09
Phase NA

What the Registry Record Tells You About NCT02409121

The ClinicalTrials.gov registry entry for NCT02409121 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Education information system is the first listed.

NCT02409121 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT02409121 about?

NCT02409121 is a clinical study titled "A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers". Hematopoietic cell transplantation (BMT), or commonly referred to as blood and marrow transplantation (BMT), is a potentially life-saving therapy for many malignant and non-malignant conditions. Despite advances over the past decade, which have led to improved outcomes, BMT remains an intense treatm...

What is the current status of trial NCT02409121?

This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2015-09. Estimated completion is 2018-12-09.

What conditions does trial NCT02409121 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia, Brain Tumor.

What interventions are being tested in trial NCT02409121?

The interventions under investigation include: Education information system (BEHAVIORAL).

Who is sponsoring clinical trial NCT02409121?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02409121 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.